BioCryst to Present at Morgan Stanley Healthcare Conference
Event summary
- BioCryst Pharmaceuticals will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, at 9:15 a.m. ET.
- The presentation will be available via live audio webcast and replay on BioCryst’s website.
- BioCryst focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
- The company has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor.
The big picture
BioCryst’s participation in the Morgan Stanley Healthcare Conference underscores its strategic focus on rare disease treatments, particularly with its lead product ORLADEYO®. The biotech sector continues to see significant investment in innovative therapies for niche indications, driven by the need for effective treatments and the potential for high margins. BioCryst’s ability to present its pipeline and commercialization strategy will be closely watched by investors and industry analysts.
What we're watching
- Pipeline Progress
- How BioCryst’s advancements in its pipeline of potential first-in-class or best-in-class therapeutics for rare diseases will impact its market position.
- Market Reception
- Whether the presentation at the Morgan Stanley conference will generate positive investor sentiment and potential partnerships.
- Commercialization Strategy
- The pace at which BioCryst can expand the commercialization of ORLADEYO® and other products in its portfolio.
Related topics